Insider Selling: Veeva Systems (NYSE:VEEV) EVP Sells $1,338,584.91 in Stock

Veeva Systems Inc. (NYSE:VEEV) EVP Daniel Rizzo sold 4,841 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $276.51, for a total value of $1,338,584.91. Following the sale, the executive vice president owned 7,665 shares in the company, valued at approximately $2,119,449.15. This trade represents a 38.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Veeva Systems Stock Down 0.5%

NYSE VEEV opened at $282.13 on Thursday. Veeva Systems Inc. has a fifty-two week low of $148.05 and a fifty-two week high of $308.36. The stock has a market cap of $45.68 billion, a price-to-earnings ratio of 46.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.93. The business has a fifty day moving average of $257.51 and a 200-day moving average of $202.22.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.12. The business had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%.The business’s revenue was up 17.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.99 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, analysts anticipate that Veeva Systems Inc. will post 6.7 EPS for the current year.

More Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Growing customer adoption: More than 175 emerging biotechnology companies are standardizing on Veeva Basics, which offers preconfigured applications across clinical, regulatory, quality, medical, and commercial functions. Faster deployments could help Veeva win customers early and expand with them as they progress toward commercialization. Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
• Positive Sentiment: Clinical-data platform gaining scale: Veeva DQS has cleaned data for more than 1 million clinical-trial subjects across over 1,000 studies and automated more than 500,000 queries. The reported time and cost savings strengthen the case for broader adoption of Veeva’s data-management products and could support recurring revenue growth. Veeva DQS Cleans Data for More Than 1 Million Subjects
• Neutral Sentiment: Valuation remains a consideration: Jim Cramer said he prefers Salesforce over Veeva among software recovery candidates, signaling that some investors may view Veeva’s rebound as less compelling despite its operating momentum. VEEV’s elevated earnings multiple also leaves the stock sensitive to any slowdown in growth or guidance. Jim Cramer Has Reservations About One of These Software Comebacks
• Negative Sentiment: Insider selling adds a modest overhang: Executive Vice President Daniel Rizzo sold 4,841 shares worth approximately $1.34 million. The filing said the transaction covered tax obligations related to vested equity awards, reducing its significance as a bearish signal, but it may still attract attention after the stock’s substantial advance.

Analysts Set New Price Targets

A number of brokerages have recently commented on VEEV. Piper Sandler lifted their price target on shares of Veeva Systems from $295.00 to $320.00 and gave the stock an “overweight” rating in a report on Thursday, August 27th. Weiss Ratings raised shares of Veeva Systems from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, August 12th. Barclays upped their price objective on shares of Veeva Systems from $275.00 to $315.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. UBS Group raised their target price on shares of Veeva Systems from $190.00 to $290.00 and gave the stock a “neutral” rating in a research report on Thursday, August 27th. Finally, Oppenheimer lifted their target price on shares of Veeva Systems from $225.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, August 17th. Nineteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $284.88.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VEEV. Czech National Bank bought a new stake in shares of Veeva Systems during the 2nd quarter worth about $7,584,000. East Coast Asset Management LLC. acquired a new stake in shares of Veeva Systems during the 1st quarter valued at about $1,665,000. WINTON GROUP Ltd bought a new stake in shares of Veeva Systems in the 4th quarter valued at approximately $3,916,000. Vulcan Value Partners LLC acquired a new position in Veeva Systems in the second quarter worth approximately $3,769,000. Finally, Rockland Trust Co. raised its position in Veeva Systems by 21.4% during the second quarter. Rockland Trust Co. now owns 173,760 shares of the technology company’s stock valued at $30,837,000 after acquiring an additional 30,678 shares in the last quarter. 88.20% of the stock is owned by hedge funds and other institutional investors.

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.